[1] |
Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults [J]. JAMA, 2013, 310(9):948-959.
|
[2] |
An Y, Zhang P, Wang J, et al. Cardiovascular and all-cause mortality over a 23-year period among chinese with newly diagnosed diabetes in the Da Qing IGT and diabetes study [J]. Diabetes Care, 2015, 38(7):1365-1371.
|
[3] |
Group AC, Patel A, Macmahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [J]. N Engl J Med, 2008, 358(3):770.
|
[4] |
Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus [J]. Am J Cardiol, 2012 , 110(6):826-833.
|
[5] |
Scirica BM, Bhatt DL, Braunwald E, et al. Committee S-TS, Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus [J]. N Engl J Med, 2013,369(14):1317-1326.
|
[6] |
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes [J]. N Engl J Med, 2013, 369(14):1327-1335.
|
[7] |
Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials [J]. Nutr Metab Cardiovasc Dis,2014, 24(7):689-697.
|
[8] |
Wu S, Hopper I, Skiba M, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55, 141 participants [J]. Cardiovasc Ther , 2014, 32(4):147-158.
|
[9] |
Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes [J]. Curr Med Res Opin, 2009, 25(10):2401-2411.
|
[10] |
Cai X, Gao X, Yang W, et al. DPP-4 inhibitor treatment in Chinese type 2 diabetes patients: a meta-analysis [J]. Diabetes Technol Ther, 2016, 18(12):784-793.
|
[11] |
Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis [J]. Circulation, 2011, 124(21):2338.
|
[12] |
Mason RP, Jacob RF, Kubant R, et al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats [J]. J Atheroscler Thromb, 2011, 18(9):774-783.
|
[13] |
Mason RP, Jacob RF, Kubant R, et al. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats [J]. J Cardiovasc Pharmacol, 2012, 60(5):467-473.
|
[14] |
杨文英. DPP-4抑制剂的心血管保护作用[J]. 中华内分泌代谢杂志, 2014, 30(1):79-82.
|
[15] |
Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease [J]. Circ Cardiovasc Imaging, 2010, 3(2):195-201.
|
[16] |
Tremblay AJ, Lamarche B, Deacon CF, et al. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes [J]. Diabetes Obes Metab, 2015, 13(4):366-373.
|
[17] |
Monami M, Vitale V, Ambrosio ML, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials [J]. Adv Ther, 2012, 29(9):736.
|